A clinical-stage biotechnology firm developing proprietary treatments for rare diseases and oncology indications with a focus on advancing pipeline candidates through clinical trials.
Investors might consider this stock if they believe in the high-value potential of the company's proprietary platform to deliver breakthrough therapies for rare diseases with limited competition. The drastic reduction in annual losses suggests improving operational efficiency or a strategic pivot that could preserve cash longer than peers. If any pipeline assets successfully advance to late-stage trials, the company could experience significant value appreciation upon potential regulatory approval.
The stock carries extreme risk given the total lack of revenue and a massive accumulated deficit of over $175M, indicating a high probability of bankruptcy without successful fundraising or asset sales. Recent revenue collapse to zero and continued heavy spending on R&D and administration leave the company with limited runway and no commercial income to offset losses. The absence of current product sales means the entire valuation is speculative and dependent on uncertain future clinical outcomes.
Dare Bioscience, Inc. (NASDAQ: DARE) is a clinical-stage biotechnology company focused on developing novel therapies for patients with rare diseases and specific cancers, primarily leveraging its proprietary platform to create targeted treatments. The company operates in the specialized biopharmaceutical sector, targeting unmet medical needs where traditional therapies have failed. Its financial profile reflects heavy investment in research and development typical of early-stage biotech firms aiming to bring new assets into clinical trials or late-stage development.
Despite a significant reduction in the annual net loss from $30.9M in 2022 to $4.1M in 2024, the company continues to operate with negative profitability and a substantial retained earnings deficit of $175.3M. Revenue has declined sharply from $10.0M in 2022 to zero in 2024, suggesting the company is currently focused on advancing its pipeline rather than commercializing products. The company maintained a healthy cash balance of $16.0M at year-end, though ongoing R&D expenditures of $14.2M and general administrative costs of $9.2M require continuous capital management.
The biotechnology industry, particularly in rare disease and oncology, offers high rewards for successful drug development but entails substantial financial risk due to long development cycles and high failure rates. Companies in this space typically require significant external capital to fund research, regulatory submissions, and clinical trials before generating any commercial revenue. Regulatory environments for rare diseases often provide incentives like orphan drug designation, which can accelerate approval but still demand robust scientific evidence.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $10.0M | $2.8M | $9.8K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $10.0M | $2.8M | $9.8K |
| Operating Expenses | $41.4M | $33.7M | $23.5M |
| Operating Income | $-31.4M | $-30.9M | $-23.5M |
| R&D | $30.0M | $21.5M | $14.2M |
| G&A | $11.2M | $12.1M | $9.2M |
| Stock-Based Comp | $2.2M | $2.5M | $2.2M |
| Depreciation | $24.2K | $38.4K | $42.3K |
| Other OpEx | $100.0K | $100.0K | $100.0K |
| Non-Operating Income | $437.5K | $780.9K | $19.4M |
| Pre-Tax Income | $-30.9M | $-30.2M | $-4.1M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-30.9M | $-30.2M | $-4.1M |
| Discontinued Ops | $262 | $-2.4K | $-1.6K |
| Net Income | $-30.9M | $-30.2M | $-4.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-30.9M | $-30.2M | $-4.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $43.0M | $17.5M | $18.4M |
| Cash & Equivalents | $34.7M | $10.5M | $15.7M |
| Other Current Assets | $8.4M | $7.1M | $2.7M |
| Long-Term Assets | $787.6K | $3.7M | $3.7M |
| PP&E (Net) | $64.9K | $656.0K | $1.3M |
| Operating Leases | $458.0K | $1.3M | $1.2M |
| Other LT Assets | $264.7K | $1.8M | $1.1M |
| Total Assets | $43.8M | $21.3M | $22.1M |
| Current Liabilities | $31.6M | $20.5M | $21.6M |
| Accounts Payable | $2.0M | $3.4M | $1.5M |
| Current Leases | $398.4K | $468.7K | $548.6K |
| Other Current Liab | $18.3M | $13.7M | $16.6M |
| Long-Term Liabilities | $1.1M | $5.8M | $6.5M |
| LT Operating Leases | $90.3K | $935.7K | $754.4K |
| Other LT Liab | $0 | $3.9M | $4.7M |
| Total Liabilities | $32.7M | $26.3M | $28.1M |
| Shareholders' Equity | $11.1M | $-5.0M | $-6.0M |
| Retained Earnings | $-141.1M | $-171.2M | $-175.3M |
| AOCI | $-351.3K | $-360.9K | $-428.8K |
| Total L&E | $43.8M | $21.3M | $22.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-30.9M | $-30.2M | $-4.1M |
| Non-Cash Adjustments | $433.1K | $-1.6M | $15.8M |
| Working Capital Changes | $12.4M | $-7.1M | $-6.4M |
| Cash from Operations | $-18.1M | $-38.9M | $5.4M |
| Capital Expenditures | $63.1K | $629.4K | $573.0K |
| Cash from Investing | $-63.1K | $-629.4K | $-573.0K |
| Cash from Financing | $1.3M | $15.6M | $433.8K |
| FX Effect | $-196.3K | $-9.6K | $-67.9K |
| Net Change in Cash | $-17.0M | $-23.9M | $5.2M |
| Beginning Cash | $51.7M | $34.7M | $10.8M |
| Ending Cash | $34.7M | $10.8M | $16.0M |
Rare Disease Therapeutics, Oncology/Cancer Treatments, and Strategic Platform Technologies
Significant financial risk due to negative net income and accumulated deficit indicating a cash-burning business model reliant on future financing; high clinical trial failure rates inherent to early-stage biotechnology development; limited current revenue streams creating vulnerability to market shifts; potential dilution from equity issuances needed to fund operations.
Proprietary drug discovery platform capable of identifying novel targets in difficult-to-treat conditions; specialized expertise in navigating rare disease regulatory pathways to accelerate patient access.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.